Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine if this specific Mycobiome Supporting Diet (MSD diet) can help reduce gut inflammation during post-transplant period. The MSD is an special diet which will be explained in detail by a dietician that works by supporting the body's good gut bacteria and fungi.

Clinical Trial Description

This is a non-randomized cohort study. Participants will be on a specific diet for 4 weeks prior to transplant and 10 days after transplant, and will then be asked to fill out several questionnaires during this period to see if this diet is easy and simple to follow. The questionnaires will be weekly while participants are outpatient and once admitted to the hospital, participants will need to fill it on the last day (10 days after stem cell infusion). Participants will also be requested to provide fecal swab samples which we will test for bacteria and fungi. A total of 3 samples will be taken at different time points during this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04685525
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact
Status	Withdrawn
Phase	N/A
Start date	April 1, 2024
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03832127` - Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients	Phase 1
Completed	`NCT01413178` - A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma	Phase 3
Recruiting	`NCT03641456` - VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma	Phase 2
Terminated	`NCT02907073` - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter	Phase 1/Phase 2
Completed	`NCT03135925` - Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation	N/A
Withdrawn	`NCT02114502` - Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma	Phase 2
Completed	`NCT00800839` - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide	Phase 2
Completed	`NCT00794261` - Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma	Phase 2
Completed	`NCT01700608` - Prospective Observational Study on Plerixafor After Chemotherapy	N/A
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Recruiting	`NCT05528887` - Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies	Phase 1
Recruiting	`NCT05625971` - Non-invasive MRD Assessment in Multiple Myeloma
Active, not recruiting	`NCT02931942` - Changing Over Time of Ascorbic Acid After Chemotherapy
Active, not recruiting	`NCT05889221` - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma	N/A
Recruiting	`NCT03836690` - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation	Phase 1
Active, not recruiting	`NCT02542657` - Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT01191060` - Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years	Phase 3
Completed	`NCT01279694` - Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)	Phase 1/Phase 2
Terminated	`NCT00983346` - Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients	Phase 2
Completed	`NCT00476294` - Long-Term Follow Up Study for AMD3100 Patients	N/A